CytomX Therapeutics, Inc. (CTMX) earnings date
Mar 15, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 27% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 38 days, typically, give or take 15 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 5, 2026 | after close | 36 | 8-K |
| Q2 FY2026 | Thu, Aug 6, 2026 | after close | 37 | 8-K |
| Q1 FY2026 | Thu, May 7, 2026 | after close | 37 | 8-K |
| Q4 FY2025 | Mon, Mar 16, 2026 | before open | 75 | 8-K |
| Q3 FY2025 | Thu, Nov 6, 2025 | after close | 37 | 8-K |
| Q2 FY2025 | Thu, Aug 7, 2025 | after close | 38 | 8-K |
| Q1 FY2025 | Mon, May 12, 2025 | before open | 42 | 8-K |
| Q4 FY2024 | Thu, Mar 6, 2025 | after close | 65 | 8-K |
What they guided beta
| Q3 FY2026 | "- Phase 1 monotherapy data update in metastatic colorectal cancer (mCRC) expected in January 2027 - - Phase 1 study in combination with bevacizumab in 3L+ mCRC ongoing." exhibit |
| Q3 FY2026 | "Phase 1/2 chemotherapy combination study in 2L mCRC expected to be initiated by year-end - - Phase 1 Varseta-M monotherapy expansion cohorts for gastric and gastroesophageal junction (GEJ) cancer, EpCAM-selected pancreatic ductal adenocarcinoma (PDAC), and EpCAM-selected biliary tract cancer (BTC) in progress - - Company to host conference call and webcast today at 5 p.m. ET / 2 p.m. PT - Emeryville, Calif., November 5, 2026 – CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced Q3 2026 financial results and provided a" exhibit |
| Q3 FY2026 | "o Announced FDA Fast Track Designation for Varseta-M for relapsed/refractory metastatic colorectal cancer in August. o A Phase 1 monotherapy mCRC data update, including dose selection and potential registrational strategy, expected in January 2027. o Potential to initiate first registrational study for Varseta-M monotherapy in mCRC in 1H 2027." exhibit |
| Q3 FY2026 | "Initial clinical data for CX-801 in combination with KEYTRUDA® in advanced melanoma is expected in the first half of 2027." exhibit |
| Q3 FY2026 | "Q3 2026 Financial Results: CytomX ended Q3 2026 with $348.0 million of cash, cash equivalents and investments with expected cash runway into the second half of 2028." exhibit |
| Q2 FY2026 | "Exhibit 99.1 CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update Varsetatug masetecan (“Varseta-M”) Program: - Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026." exhibit |
| Q2 FY2026 | "As of the end of April 2026, enrollment in the dose optimization cohorts reached the goal of 40 patients across the 8.6 mg/kg Q3W and 10 mg/kg Q3W doses 1 . o A Phase 1 data update is expected by the end of 2026 with a focus on dose selection for late phase development." exhibit |
| Q2 FY2026 | "Initial clinical data for CX-801 in combination with KEYTRUDA® in advanced melanoma is expected in the first half of 2027." exhibit |
| Q2 FY2026 | "Financial: o CytomX ended Q2 2026 with $330.3 million of cash, cash equivalents and investments with expected cash runway to at least the second half of 2028." exhibit |
| Q2 FY2026 | "The decrease in revenue was driven primarily by the completion of the Company’s performance obligation during 2025 in the collaborations with Bristol Myers Squibb and lower research activities in the Astellas collaboration which concluded in the second quarter of 2026." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/CTMX
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/CTMX
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/CTMX/"><img src="https://veritasdata.dev/embed/CTMX.svg" alt="CTMX earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/CTMX/)
Script
<script async src="https://veritasdata.dev/embed/CTMX.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/CTMX"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.